[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618070":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":33,"centralContacts":37,"locations":43,"responsibleParty":62,"collaborators":65,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":72,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":33,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":100,"whyStopped":33,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"General Hospital of Shenyang Military Region","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"the experimental Group","EXPERIMENTAL","The experimental Group received orlistat 120mg tid+ standard ULT (e.g., febuxostat 40mg qd) + basic lifestyle advice (low-purine diet and exercise guidance).",[13,14,15],"Drug: Orlistat 120 mg","Drug: Allopurinol 100 up to 600mg\u002Fday","Drug: Febuxostat 40mg Tab",{"label":17,"type":18,"description":19,"interventionNames":20},"The control group","PLACEBO_COMPARATOR","The control group received placebo matching orlistat (tid) + standard ULT (e.g., febuxostat 40mg qd) + basic lifestyle advice (low-purine diet and exercise guidance).",[14,15],[22,29,34],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Orlistat 120 mg","Oral capsule, taken after meals, 120 mg three times daily (tid) for 24 weeks.",[9],[28],"Orlistat 120 mg tid",{"type":23,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"Allopurinol 100 up to 600mg\u002Fday","Standard urate-lowering therapy (e.g., allopurinol or febuxostat), with doses adjusted based on serum uric acid levels and liver\u002Fkidney function.",[17,9],null,{"type":23,"name":35,"description":31,"armGroupLabels":36,"otherNames":33},"Febuxostat 40mg Tab",[17,9],[38],{"name":39,"role":40,"phone":41,"phoneExt":33,"email":42},"XueMei GUO, MS","CONTACT","+86-24-28853148","490422665@qq.com",[44],{"facility":45,"status":33,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"General Hospital of Northern Theater Command, PLA","Shenyang","Liaoning","110016","China","CN",{"type":52,"coordinates":53},"Point",[54,55],123.43278,41.79222,{"lat":55,"lon":54},[58],{"name":59,"role":40,"phone":60,"phoneExt":33,"email":61},"Ping Li, Ph D","02428853148","graceli008@sohu.com",{"type":63,"investigatorFullName":64,"investigatorTitle":5,"investigatorAffiliation":5,"oldNameTitle":33,"oldOrganization":33},"SPONSOR_INVESTIGATOR","XueMei Guo",[66,68],{"name":67,"class":6},"Shengjing Hospital",{"name":69,"class":6},"The People's Hospital of Liaoning Province","100618070","orlistat-and-weight-management-for-uric-acid-control-in-obese-gout-a-rct-100618070",false,"NCT07326839","Orlistat and Weight Management for Uric Acid Control in Obese Gout: A RCT","Optimization of Blood Uric Acid Control in Obese Gout Patients by Orlistat-Mediated Metabolic Remodeling and Intensive Weight Management: A Randomized Controlled Trial","OWMUAC","Inclusion Criteria:\n\n1. Meeting the 2015 ACR\u002FEULAR classification criteria for gout.\n2. Age 18-70 years.\n3. BMI ≥28 kg\u002Fm².\n4. Serum uric acid ≥480 μmol\u002FL.\n5. Willing and able to comply with the study protocol.\n\nExclusion Criteria:\n\n1. Contraindications to orlistat or other gout medications.\n2. Severe hepatic or renal dysfunction.\n3. History of severe allergy or adverse reactions to study drugs.\n4. Pregnant or lactating women.\n5. Malignancy.\n6. Secondary gout.\n7. Poor compliance or inability to cooperate.\n8. Participation in other clinical trials within the last 3 months.","ALL","18 Years","70 Years",{"count":82,"type":83},120,"ESTIMATED","INTERVENTIONAL",[86],"NA","A total of 120 obese gout patients were included in a 24-week double-blind randomized controlled design. The intervention group received orlistat 120 mg tid + UTL + individualized diet-exercise-behavioral reinforcement weight loss program, while the control group received a placebo + UTL + standard recommendations. The primary endpoint was the rate of achieving serum uric acid levels \\\u003C360 μmol\u002FL at 24 weeks; secondary endpoints included the proportion of weight loss ≥5%, frequency of gout attacks, and inflammatory indicators such as CRP and IL-1β; the activity of AMPK in PBMCs and the expression of HIF1α and NLRP3 inflammasome-related proteins were also assessed.",[89,90],"Gout","Obesity",[92,89,93,94,95,96,97,98,99],"Obese","Orlistat","Metabolic Reprogramming","Weight Control","Uric acid","AMPK","HIF1","NLRP3","NOT_YET_RECRUITING","2026-01-07",{"date":103,"type":104},"2026-01-08","ACTUAL",{"date":106,"type":83},"2025-12-10",{"date":108,"type":83},"2027-11-09",{"name":64,"class":6},1]